Characterizing contrast-enhancing and re-enhancing lesions in multiple sclerosis

Neurology

Volumn 78, Issue 19, 2012, Pages 1493-1499

  Campbell, Z ^a   Sahm, D ^a   Donohue, K ^a   Jamison, J ^a   Davis, M ^a   Pellicano, C ^a   Auh, S ^b   Ohayon, J ^a   Frank, J A ^d   Richert, N ^a   Bagnato, F ^c  

^a Neuroimmunology Branch (NIB)   (United States)

^b Office of the Director   (United States)

^c NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^d Radiology and Imaging Sciences Clinical Canter   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; DEMOGRAPHY; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

EID: 84863615272     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182553bd2     Document Type: Article

References (27)

1. Neema M, Stankiewicz J, Arora A, et al. MRI in multiple sclerosis: what's inside the toolbox? Neurotherapeutics 2007;4:602-617
2. Miller DH, Grossman RI, Reingold SC, et al. The role of magnetic resonance techniques in understanding and managing multiple sclerosis. Brain 1998;121:3-24
3. Harris JO, Frank JA, Patronas N, et al. Serial gadoliniumenhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: Implications for clinical trials and natural history. Ann Neurol 1991;29:548-555
4. McFarland HF, Frank JA, Albert PS, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor the activity in multiple sclerosis. Ann Neurol 1992;32:758-766
5. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34: 661-669
6. Barkhof F, Scheltens P, Frequin ST, et al. Relapsingremitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity. AJR Am J Roentgenol 1992;159:1041-1047
7. Ciccarelli O, Giugni E, Paolillo A, et al. Magnetic resonance outcome of new enhancing lesions in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 1999; 6:455-459
8. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes." Neurology 2001;57:731-733
9. Gupta S, Solomon JM, Tasciyan TA, et al. Interferon-b-1b effects on re-enhancing lesions in patients with multiple sclerosis. Mult Scler 2005;11:658-668
10. Koopmans RA, Li DK, Oger JJ, et al. The lesion of multiple sclerosis: imaging of acute and chronic stages. Neurology 1989;39:959-963
11. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62
12. Kwon EE, Prineas JW. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions: an immunohistochemical study. J Neuropathol Exp Neurol 1994;53: 625-636
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452
14. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
15. Richert ND, Ostuni JL, Bash CN, et al. Serial whole-brain magnetization transfer imaging in patients with relapsingremitting multiple sclerosis at baseline and during treatment with interferon beta-1b. AJNR Am J Neuroradiol 1998;19:1705-1713
16. Prineas JW, Barnard RO, Revesz T, et al. Multiple sclerosis: pathology of recurrent lesions. Brain 1993;116:681-693
17. De Groot CJ, Bergers E, Kamphorst W, et al. Postmortem MRI-guided sampling of multiple sclerosis brain lesions: increased yield of active demyelinating and (p) reactive lesions. Brain 2001;214:1635-1645
18. Kirk J, Plub J, Mirakhur M, et al. Tight junctional abnormality in multiple sclerosis white matter affects all calibers of vessel and is associated with blood-brain barrier leakage and active demyelination. J Pathol 2003; 201:319-327
19. Silver NC, Tofts PS, Symms MR, et al. Quantitative contrast-enhanced magnetic resonance imaging to evaluate blood-brain barrier integrity in multiple sclerosis: a preliminary study. Mult Scler 2001;7:75-82
20. Soon D, Altmann DR, Fernando KT, et al. A study of subtle blood brain barrier disruption in a placebocontrolled trial of natalizumab in relapsing remitting multiple sclerosis. J Neurology 2007;254:306-314
21. Soon D, Tozer DJ, Altmann DR, et al. Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes. Mult Scler 2007;13:884-894
22. van Waesberghe JH, van Walderveen MA, Castelijns JA, et al. Patterns of lesions development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. AJNR Am J Neuroradiol 1998;19:675-683
23. Bagnato F, Jeffries N, Richert ND, et al. Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 2003;126:1782-1789
24. Rovira A, Alonso J, Cucurella G, et al. Evolution of multiple sclerosis lesions on serial contrast-enhanced T1- weighted and magnetization-transfer MR images. Am J Neuroradiol 1999;20:1939-1945
25. Balaban RS, Ceckler TL. Magnetization transfer contrast in magnetic resonance imaging. Magn Reson Q 1992;8: 116-137
26. Filippi M, Rocca MA, Horsfield MA, Comi GA. one year study of new lesions in multiple sclerosis using monthly gadolinium enhanced MRI: correlations with changes of T2 and magnetization transfer lesion loads. J Neurol Sci 1998;158:203-208
27. Stankiewicz JM, Glanz BI, Healy BC, et al. Brain MRI lesion load at 1.5 T and 3T versus clinical status in multiple sclerosis. J Neuroimaging 2011;21:e50-e56.